Compare · PFE vs UPC
PFE vs UPC
Side-by-side comparison of Pfizer Inc. (PFE) and Universe Pharmaceuticals Inc. (UPC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PFE and UPC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $153.59B, about 83120.4x UPC ($1.8M).
- Over the past year, PFE is up 17.1% and UPC is down 50.6% - PFE leads by 67.7 points.
- PFE has been more active in the news (10 items in the past 4 weeks vs 1 for UPC).
- PFE has more recent analyst coverage (25 ratings vs 0 for UPC).
- Company
- Pfizer Inc.
- Universe Pharmaceuticals Inc.
- Price
- $26.98+1.20%
- $2.89-0.69%
- Market cap
- $153.59B
- $1.8M
- 1M return
- -1.21%
- +19.42%
- 1Y return
- +17.13%
- -50.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 1
- Recent ratings
- 25
- 0
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Universe Pharmaceuticals Inc.
Universe Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief for common chronic health conditions in the elderly for the physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'an, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities
Latest UPC
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 3 filed by new insider Yang Lin (Lydia)
- SEC Form 3 filed by new insider Lai Gang
- SEC Form 3 filed by Universe Pharmaceuticals Inc.
- SEC Form 6-K filed by Universe Pharmaceuticals Inc.
- Universe Pharmaceuticals INC Announces Effective Date of Dual-Class Share Structure
- SEC Form 20-F filed by Universe Pharmaceuticals Inc.